Tandem Diabetes Care (TNDM) | Stock Overview & Key Data
Tandem Diabetes Care Performance Comparison
Stock Range
Today's Range
Low: $10.44
High: $11.17
on August 21, 2025
52 Week Range
Low: $9.98
High: $47.60
on September 25, 2024
All-Time High: $302.50 on January 13, 2014
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$735.8M
EPS
-3.08
P/E Ratio (TTM)
-7.27
Forward P/E
-9.00
P/B Ratio
5.52
PEG Ratio
-0.11
Div. Yield
N/A
ROE
-111.92%
Beta
1.472
Debt to Equity
340.56
Financial Highlights
Profitability
Gross Margin
52.29%
Operating Margin
-13.24%
Profit Margin
-20.51%
Returns and Earnings
Return on Assets (TTM)
-6.41%
Return on Equity (TTM)
-111.92%
EBITDA
$-75.9M
Net Income (TTM)
$-205.5M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$15.12
Quarterly Revenue Growth (YoY)
8.50%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Tandem Diabetes Care TNDM | 735.83M Small-cap | 3.66% | -24.47% | -48.96% | -64.35% | -69.17% | -75.22% | -76.33% | -90.22% |
| Abbott Laboratories ABT | 229.31B Mega-cap | 2.10% | 6.09% | -0.79% | -2.16% | 16.36% | 17.14% | 29.54% | 19.14% |
| Boston Scientific BSX | 153.73B Large-cap | 1.02% | 1.38% | 0.54% | 0.69% | 17.71% | 32.89% | 159.65% | 156.42% |
| QuidelOrtho QDEL | 1.78B Small-cap | -1.12% | 1.42% | -13.25% | -36.58% | -43.03% | -42.99% | -68.73% | -84.25% |
| Enovis ENOV | 1.69B Small-cap | 2.36% | 12.17% | -8.81% | -30.93% | -33.41% | -35.91% | -43.59% | -48.99% |
| Conmed CNMD | 1.69B Small-cap | 0.82% | 10.93% | -7.56% | -13.19% | -21.20% | -26.24% | -42.25% | -38.83% |
Ownership & Short Interest
Insider Ownership
0.95%
Institutional Ownership
121.22%
Shares Short
9M
Short Ratio
4.75
Short % of Shares Outstanding
17.95%
Average 10-Day Volume
4M
Average 90-Day Volume
2M
Tandem Diabetes Care Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Tandem Diabetes Care would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is TNDM's 52-week high and low?
- In the last 52 weeks, Tandem Diabetes Care reached a high of $47.60 (on September 25, 2024) and a low of $9.98 (on N/A).
- What is the market cap and P/E ratio for TNDM?
- Curious about Tandem Diabetes Care's size and valuation? Its market capitalization stands at 735.83M. When it comes to valuation, the P/E ratio (trailing twelve months) is -7.27, and the forward P/E (looking ahead) is -9.00.
- Does TNDM pay dividends? If so, what's the yield?
- As for dividends, Tandem Diabetes Care isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Tandem Diabetes Care's main competitors or similar companies to consider before investing?
When looking at Tandem Diabetes Care, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT229.31B Healthcare Medical Devices 17.14% 29.54% Boston Scientific
BSX153.73B Healthcare Medical Devices 32.89% 159.65% QuidelOrtho
QDEL1.78B Healthcare Medical Devices -42.99% -68.73% Enovis
ENOV1.69B Healthcare Medical Devices -35.91% -43.59% Conmed
CNMD1.69B Healthcare Medical Devices -26.24% -42.25% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Tandem Diabetes Care Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Tandem Diabetes Care's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -111.92%, the Debt to Equity ratio from the most recent quarter is 340.56, and its Gross Profit Margin stands at 52.29%.
- What is the recent revenue and earnings growth for TNDM?
- Looking at Tandem Diabetes Care's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 8.50%, and quarterly earnings saw a YoY growth of N/A.
- How much of TNDM stock is held by insiders and institutions?
- Wondering who owns Tandem Diabetes Care stock? Company insiders (like executives and directors) hold about 0.95% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 121.22%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.